Increased secretion of IL-8 and IL-6 promotes the expression of BC resistance protein (BRCP) by activating the AKT and STAT3 signaling pathways, respectively, which induce doxorubicin treatment resistance by accelerating efflux from BC cells. Here, STAT3 is linked to breast cancer.